Transforming systemic therapy selection through molecular insight

Traditionally, clinicians lack objective, molecular-based information to guide treatment selection in patients with moderate-to-severe atopic dermatitis (AD) — hindering optimal therapy selection.

Now, with AdvanceAD-Tx clinicians have the opportunity to match therapy to an individual's immune profile using objective molecular testing, personalizing treatment for their patients.

A common disease

Atopic dermatitis is a very common disease, affecting a significant portion of the population.

The unseen complexity of disease biology

Beneath the skin's surface, a complex and diverse set of immune changes drive the disease.

A first-in-class, non-invasive test to personalize treatment in atopic dermatitis

For many people living with moderate-to-severe AD, systemic therapy doesn’t always deliver the results they hoped for. They may try multiple therapies, cycling through different options with unsatisfactory improvement in their AD. This treatment cycling may happen because it's hard to know what is driving the disease beneath the skin.

TODAY

THERAPY CYCLING

Currently treament cycling leads to

Higher healthcare costs
Lost time due to ineffective treament
Patient frustration
Clinician frustration

A NEW APPROACH
‍

PERSONALIZED MEDICINE

AdvanceAD-Tx helps guide treatment choices by revealing the biology driving each patient's disease, giving clinicians and patients confidence to select a systemic therapy that aligns with their underlying biology from the start.

Patient stratification by gene expression profiling

‍

AdvanceAD-Tx measures the expression of 487 genes across 12 skin and inflammatory pathways linked to AD using a validated neural algorithm to guide systemic treatment decision making for patients.

Hear from an expert

Shannon Trotter, DO discusses the challenges she faces when treating patients with AD and how AdvanceAD-Tx can help guide her decisions.

NEXT UP